Compositions and methods of treating cancer

A composition and molecular technology, applied in the fields of biological sciences and cancer research, can solve the problems of very early detection of precancerous states, etc.

Inactive Publication Date: 2010-08-04
ONCOTHERAPY SCI INC
View PDF31 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, this method is limited because the results it gives are subjective and cannot be used for very early detection of precancerous states

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods of treating cancer
  • Compositions and methods of treating cancer
  • Compositions and methods of treating cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0403] [Example 1] General method

[0404] tissue preparation

[0405] After preoperative informed consent of patients, 34 patients (bladder cancer), 25 patients (cholangiocarcinoma), 48 patients (colon cancer), 64 patients (esophageal cancer), 59 patients ( Prostate cancer), 15 patients (SCLC), 18 patients (pancreatic cancer), 37 patients (NSCLC), 81 patients (breast cancer), clinical bladder cancer, cholangiocarcinoma, colon cancer, esophageal cancer, Prostate, Small Cell Lung Cancer (SCLC), Pancreatic, Non-Small Cell Lung Cancer (NSCLC), and Breast Cancer samples.

[0406] cDNA microarray

[0407] Preparation of cDNA microarray slides has been described elsewhere (Zembutsu H et al., Cancer Res 2002 Jan 15, 62(2):518-2.; Nishidate T et al., Int J Oncol 2004 Oct, 25(4) : 797-819). To analyze the different cancer expression profiles, the inventors prepared duplicate sets of slides containing 23,040 (colon, soft tissue sarcomas, and testicular seminomas, prostate cancers) o...

Embodiment 2

[0443] [Example 2] Screening for upregulation in clinical cancer samples but no expression or low expression in normal organs genetic

[0444]cDNA microarray analysis was performed as previously described (Zembutsu H et al., Cancer Res 2002 Jan 15, 62(2): 518-27; Nishidate T et al., Int J Oncol 2004 Oct, 25(4): 797 -819). Genes that were generally upregulated in clinical cancer tissues were selected by comparison of expression patterns between cancer tissues and corresponding normal epithelium. Next, semi-quantitative RT-PCR analysis was performed to select cancer-specific genes that were detected to be highly expressed in cancer cell lines but not in corresponding normal organs and normal vital organs ( figure 1 ). Genes that are highly expressed in normal organs are excluded in case such genes may induce fatal side effects when such genes are used as target genes for inhibition in therapy.

Embodiment 3

[0445] [Example 3] Design of custom siRNA for candidate

[0446] Utilize the siRNA design provided on Ambion's website (http: / / www.ambion.com / techlib / misc / siRNA_finder.html) (Tuschl T et al., Genes Dev 1999 Dec 15, 13(24):3191-7) The tool designs siRNA sequences for each candidate gene to select candidate siRNA sequences. Each siRNA was introduced into cancer and control cells and their relative cell viability was assessed to obtain the most effective sequence for inhibiting cell growth (Table 1).

[0447] [Table 1]

[0448] siRNA sequences designed for 4 candidate genes

[0449]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention features a method for treating cancer by administering a double-stranded nucleic acid molecule against a CX gene selected from the group consisting of C14orf78, MYBL2, UBE2S and UBE2T. The invention also features products, including the double-stranded nucleic acid molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods. The methods of the invention are suited for the treatment of cancers including lung cancer, breast cancer, bladder cancer, esophagus cancer, prostate cancer, cholangiocellular carcinoma and testicular seminoma.

Description

technical field [0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Application Serial No. 60 / 937,616, filed June 27, 2007, which is hereby incorporated by reference in its entirety. technical field [0003] The present invention relates to the field of biological sciences, more particularly to the field of cancer research. In particular, the present invention relates to double-stranded nucleic acid molecules that inhibit the expression of a CX gene selected from the group consisting of C14orf78, MYBL2, UBE2S and UBE2T genes, and compositions comprising said double-stranded nucleic acid molecules. The invention further relates to methods of treating cancer using said molecules or compositions. Background technique [0004] Pancreatic cancer (ductal adenocarcinoma of the pancreas) [0005] In Western countries, pancreatic ductal adenocarcinoma (PDAC) ranks fourth among the leading causes of cancer death and is o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/00A61K31/7105A61K48/00A61P35/00
CPCC12N15/113C12N2310/14A61P35/00
Inventor 富樫亮飞田隆太郎石崎优香小沼亚希子
Owner ONCOTHERAPY SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap